Proactiveinvestors recommends
Additional Information
Market: LSE
Sector: Pharmaceuticals
EPIC: BII
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Biocompatibles
www.biocompatibles.com

Biocompatibles International plc is a leading company in the field of drug-device combination products.  The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products.  These include products that are used for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and prostate cancer.  Our R&D Facilities are engaged in licensing and in new product development for oncology, stroke, and diabetes and obesity.  We have collaborative agreements with AstraZeneca, Bayer Healthcare Pharmaceuticals Inc. and Medtronic Inc.

Full Biocompatibles profile here
Pdf

Biocompatibles liver cancer treatment submitted for marketing approval in Japan

17th Dec 2010, 3:34 pm

Biocompatilbles’ (LON:BII) partner Eisai Co has applied for approval to market the UK company’s embolic bead E7040 in Japan, which is used to treat liver cancer.

The Japanese Ministry of Health recommended the bead be made available as early as possible at a meeting last January.

Biocompatibles chief executive Crispin Simon said: "We congratulate Eisai on submission of the DC bead Marketing Authorisation. 

“The designation of DC Bead for fast track registration in Japan recognises the benefits this product brings over conventional therapies, and the size of the Japanese HCC patient population."

Last month Biocompatibles accepted a bid from drug developer BTG (LON:BGC), which values the company at 430p a share, or £177.2 million in total.

Biocompatibles recommended the offer because it said it believed the deal will create a “fast-growing, financially stronger, international specialist healthcare business”.

The pair said the transaction is about harnessing the growth potential of Biocompatibles, whose drug delivery beads are used in oncology.

They will have cash resources of around £97 million to tap into and a number of other innovations to take into the marketplace.

Investors are being offered 1.6733 BTG shares for each Biocompatibles share they own plus 10p in cash. 

Alternatively they can pass on the 10p cash payment and opt instead for contingent value notes up to the value of 47p (56 euros), which are linked to the development of GLP-1 for diabetes and obesity. 

Shareholders accounting for 53.19 per cent of Biocompatibles stock have irrevocably committed to backing the deal, while a further 10.49 per cent have said they intend to back the offer.

The acquisition is being done via a scheme of arrangement, which requires 75 per cent support from investors.

 

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.